Enterprise Value

512.4M

Cash

322M

Avg Qtr Burn

-27.78M

Short % of Float

5.54%

Insider Ownership

7.76%

Institutional Own.

93.74%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KER-012 Details
Pulmonary hypertension, Cardiovascular disease

Phase 2

Data readout

KER-050 Details
Blood cancer, Cystic fibrosis, Lung disease, Myelofibrosis, Cancer

Phase 2

Data readout

KER-050 Details
Blood disorder, Cancer, Myelodysplastic syndrome

Phase 2

Data readout

KER-065 Details
Duchenne muscular dystrophy, Neuromuscular disease

Phase 1

Initiation

KER-047 (ALK2 inhibitor) Details
Myelodysplastic syndrome, Myelofibrosis

Failed

Discontinued

KER-047 (ALK2 inhibitor) Details
Fibrodysplasia ossificans progressiva, Anemia

Failed

Discontinued